Evaluation of the Therapeutic Effect of Platelet Rich Plasma (PRP) in Periorbital Hyperpigmentati… (NCT03862118) | Clinical Trial Compass
UnknownPhase 3
Evaluation of the Therapeutic Effect of Platelet Rich Plasma (PRP) in Periorbital Hyperpigmentation(POH)
30 participantsStarted 2019-11-01
Plain-language summary
To evaluate the saftey and efficicacy of autologous PRP in treatment of POH.
Who can participate
Age range20 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* •Both sexes will be included.
* Age (20-50)
* Patient with Fitzpatrick skin types III-IV
Exclusion Criteria:
* • Patients with known platelet dysfunction syndrome, critical thrombocytopenia (\<50,000/ul), any hemodynamic instability.
* Patients with chronic medical illness (e.g. diabetes, chronic infections, and blood dyscrasias).
* Patients with local inflammatory skin disorders or active herpes infection at the site of the procedure.
* Patients on consistent use of anti-coagulants or non-steroidal anti-inflammatory drugs (NSAID) within 48 hours of procedure.
* Haemoglobin level\< 10 g/dl were also excluded.
* Patients with cancer- especially hematopoietic or of bone.
* Pregnant females.
* Patients with corticosteroids injection at treatment site within 1 month or systemic use of corticosteroids within 2 weeks.